Evaluate T cell response


Evaluating the T cell response induced by a biotherapeutic protein is now commonly used as a surrogate marker for the risk of developing anti-drug antibodies (ADA) in the clinic. The Epibase® in vitro T cell assay platform takes into account not just the intrinsic T cell epitopes contained within the amino  acid  sequence of the  protein, but also a host of other factors that can contribute to immunogenicity  risk, including protein structure, PTMs, aggregates, production contaminants and formulation components. T cell responses against whole proteins, protein fragments, short synthetic peptides or peptide pools can be assessed in healthy donor PBMCs. Additionally, these assays can be used to monitor the strength and quality of the immune response during clinical trials.

T Cell Assay Formats

  • PBMC-based assays using flow cytometry to assess CD4+ and/or CD8+ T cell proliferation as well as B cell proliferation
  • Highly sensitive DC:CD4 and DC:CD8 re-stimulation assays using a multi-color FluoroSpot readouts of T cell activation (IFNγ/IL-5 and IFNγ/Granzyme B readouts respectively)
  • Large cytokine/chemokine panels using Luminex® to characterize the T cell response
  • Memory assays for the assessment of T and B cell responses during clinical trials